AI Verdict
MBLY has stronger fundamentals based on our AI analysis.
MBX vs MBLY Fundamental Comparison
| Metric | MBX | MBLY |
|---|---|---|
| Revenue | N/A | $1.9B |
| Net Income | $-87.0M | $-392.0M |
| Net Margin | N/A | -20.7% |
| ROE | -23.6% | -3.3% |
| ROA | -22.6% | -3.1% |
| Current Ratio | 24.62x | 6.10x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | $-2.38 | $-0.48 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
MBX vs MBLY: Frequently Asked Questions
Is MBX or MBLY a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MBLY has stronger fundamentals. MBX is rated STRONG SELL (92% confidence) while MBLY is rated HOLD (62% confidence). This is not investment advice.
How does MBX compare to MBLY fundamentally?
MBX Biosciences, Inc. has ROE of -23.6% vs Mobileye Global Inc.'s -3.3%. Net margins are N/A vs -20.7% respectively.
Which stock pays higher dividends, MBX or MBLY?
MBX has a dividend yield of N/A or no dividend while MBLY has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in MBX or MBLY for long term?
For long-term investing, consider that MBX has STRONG SELL rating with 92% confidence, while MBLY has HOLD rating with 62% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about MBX vs MBLY?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For MBX vs MBLY, the AI consensus favors MBLY based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.